Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 2 Recurrence 1 Lymphoma, Large B-Cell, Diffuse 1

Interventions

tisagenlecleucel 2 fludarabine 2 blinatumomab 2 Cyclophosphamide 2 zanubrutinib 1 selinexor 1 revumenib 1 niraparib 1 nilotinib 1 ivosidenib 1 imetelstat 1 ibrutinib 1 entrectinib 1 dostarlimab 1 brexucabtagene autoleucel 1 avapritinib 1 asciminib 1 Standard of Care 1 Paclitaxel 1 Imatinib Mesylate 1 GRN163L peptide 1 Drug Therapy 1 Dexamethasone 1 Dasatinib 1 Carboplatin 1 Bortezomib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Recurrence × selinexor × Clear all

NCT03110562 2024-08-21

BOSTON

Karyopharm Therapeutics Inc

Phase 3 Completed

402 enrolled 22 charts 1 FDA

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡